Long-acting regimen noninferior to daily ART for HIV-1
(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...
Mar 12, 2019
0
2